Clinical Pharmacokinetics and Pharmacodynamics of Cholinesterase Inhibitors

被引：0
作者：
Michael W. Jann
Kara L. Shirley
Gary W. Small
机构：
[1] Mercer University,Department of Clinical and Administrative Sciences, Southern School of Pharmacy
[2] Albany College of Pharmacy,Department of Pharmacy Practice
[3] University of California,Department of Psychiatry and Biobehavioral Sciences, Center on Aging and Alzheimer’s Disease Research Center
[4] Mercer University,Southern School of Pharmacy
来源：
Clinical Pharmacokinetics | 2002年 / 41卷
关键词：
Cholinesterase; Fluvoxamine; Cholinesterase Inhibitor; Rivastigmine; Tacrine;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Cholinesterase inhibitors are the ‘first-line’ agents in the treatment of Alzheimer’s disease. This article presents the latest information on their pharmacokinetic properties and pharmacodynamic activity.
引用
收藏
页码：719 / 739
页数：20
相关论文
共 249 条
[11]  
Perry E.K.(1994)Tacrine: first drug approved for Alzheimer’s disease Ann Pharmacother 28 744-51
[12]  
Practico D.(1995)Clinical pharmacokinetic of drugs for Alzheimer’s disease Clin Pharmacokinet 29 110-29
[13]  
Delanty N.(1989)Pharmacokinetics of tacrine hydrochloride in Alzheimer’s disease Clin Pharmacol Ther 46 634-41
[14]  
Jick H.(1990)Steady-state pharmacokinetics of tacrine in patients with Alzheimer’s disease Psychopharmacol Bull 26 231-4
[15]  
Zornberg G.L.(1990)Clinical pharmacokinetics of intravenous and oral 9-amino-1,2,3,4-tetrahydroacridine, tacrine Eur J Clin Pharmacol 38 259-63
[16]  
Jick S.S.(1995)Clinical pharmacokinetics of tacrine Clin Pharmacokinet 28 449-57
[17]  
Small G.W.(1998)Cholinesterase inhibitors in the treatment of Alzheimer’s disease Drug Saf 19 465-80
[18]  
Rabins P.V.(1994)Tacrine: a review of its pharmacological and pharmacokinetic properties and therapeutic potential in Alzheimer’s disease Drugs Aging 4 1-31
[19]  
Barry P.P.(1994)Plasma protein binding characteristics of tacrine hydrochloride (THA) [abstract] Br J Clin Pharmacol 38 489P-81
[20]  
Imbimbo B.P.(1998)Penetration of tacrine into cerebrospinal fluid in patients with Alzheimer’s disease J Clin Psychopharmacol 18 78-7
12345678910